Core Insights - SOPHiA GENETICS has announced a significant expansion in the United States by partnering with two major integrated health systems, enhancing its network and capabilities in AI-driven precision medicine [1] Company Expansion - The two new health systems are among the largest in the U.S., collectively analyzing millions of genetic samples annually [1] - The partnership will enable genomic testing for up to 60,000 patients annually across the West Coast and Midwest, focusing on hereditary cancers and rare diseases [1] Technology Utilization - Both health systems will implement SOPHiA DDM™, an AI-driven analytics application that supports comprehensive full-exome analysis for over 20,000 genes [1] - The integration of SOPHiA DDM™ aims to expedite testing turnaround times, reduce operational costs, and foster internal research and innovation initiatives [1] Market Positioning - This collaboration positions SOPHiA GENETICS and its partners to support future expansion in AI-driven precision medicine, serving a combined population of nearly one million cancer and rare disorder patients nationwide [1] - The expansion reinforces the company's mission to democratize data-driven medicine by providing AI-powered solutions that accelerate healthcare innovation and research [1]

Core Viewpoint - SOPHiA GENETICS reported strong preliminary financial results for Q4 and full year 2025, with expectations of 20-22% revenue growth in 2026 and announced an executive transition plan promoting Ross Muken to CEO effective July 1, 2026 [1][2][3] Financial Performance - Q4 2025 revenue is projected to be at least $21 million, reflecting a year-over-year increase of approximately 20% [6] - The company performed over 105,000 analyses on SOPHiA DDM™ in Q4 2025, marking a 16% year-over-year growth [6] - Full year 2025 revenue is approximately $77 million, representing an 18% year-over-year increase [6] - The total revenue for 2026 is guided to be between $92 million and $94 million, indicating a year-over-year growth of approximately 20% to 22% [7] Executive Transition - Ross Muken, currently President and a key executive for five years, will succeed Jurgi Camblong as CEO [3][5] - Jurgi Camblong will transition to Executive Chairman, focusing on strategic initiatives and technology innovation [4][5] - Kevin Puylaert has been appointed Chief Sales Officer effective January 2026, bringing over 10 years of experience with the company [10] Growth Catalysts - The company anticipates growth drivers in 2026, including advancements in its Liquid Biopsy application MSK-ACCESS powered by SOPHiA DDM™, opportunities in the U.S. market, and a revitalized BioPharma business [2]

Core Insights - Complete Genomics and SOPHiA GENETICS have announced a collaboration to co-market MSK-ACCESS® and MSK-IMPACT® powered by SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform, aiming to enhance access to precision oncology testing globally [1][2]. Group 1: Collaboration Details - The partnership integrates SOPHiA GENETICS' AI-powered applications with Complete Genomics' DNBSEQ-T1+ platform, providing a sample-to-report workflow for laboratories [2]. - This collaboration marks a significant expansion into the precision oncology research market, enhancing the capabilities of both companies [2][3]. Group 2: Technology and Performance - The DNBSEQ-T1+ platform offers Q40-level accuracy and optimized throughput ranging from 500 million to 2 billion reads per flow cell, with a 24-hour paired-end 150bp run time [3]. - Each flow cell can run up to 60 tumor-normal sample pairs for tissue and up to 16 for liquid biopsy, providing a cost-effective and flexible sequencing solution [3]. Group 3: Benefits and Impact - The collaboration aims to enable decentralized labs to deliver faster, more accurate, and affordable insights to clinicians and researchers [3]. - SOPHiA DDM™ is a technology-agnostic analytics platform that enhances the analysis of healthcare data, demonstrating lower background noise and reduced turnaround time compared to other systems [4]. Group 4: Market Positioning - This new offering provides clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient path for implementing comprehensive genomic profiling in precision oncology research [5]. - The collaboration is positioned to broaden access to data-driven medicine, allowing more laboratories worldwide to adopt precision oncology solutions [3][4].

Core Insights - SOPHiA GENETICS and Element Biosciences announced a partnership to integrate sequencing and AI analytics, aiming to enhance genomic workflows and support precision medicine research [1][2][4] Company Overview - SOPHiA GENETICS is a leader in AI-driven precision medicine, focusing on expanding access to data-driven healthcare through its SOPHiA DDM™ platform [8] - Element Biosciences is transforming scientific discovery with advanced technologies that enhance the pace and accessibility of genomics [9] Partnership Details - The collaboration combines SOPHiA DDM™ with Element's AVITI24™ 5D multiomic and AVITI sequencing systems, creating a streamlined end-to-end workflow for next-generation sequencing (NGS) [2] - This integration is expected to provide speed, scalability, and flexibility, allowing clinical researchers to derive actionable insights from NGS data efficiently [2][4] Expected Impact - The partnership aims to democratize access to genomic research, enabling healthcare organizations of all sizes to adopt innovative, AI-driven technologies [4] - The collaboration is anticipated to enhance the accuracy and consistency of genomic testing, ultimately accelerating the delivery of precision medicine to more patients [3][4]

Company Overview and Platform - SOPHiA GENETICS' AI platform SOPHiA DDM™ is used by over 800 healthcare institutions globally[7] - The platform analyzes over 350,000 patients per year[8, 21] and has analyzed over 2 million profiles since its inception[8] - The company has invested over $400 million since its inception to develop AI Factories and proprietary algorithms[21, 53] Market Trends and Data Analysis - Healthcare data accounts for 30% of all data generated globally[16] - In Q3 2025, SOPHiA GENETICS analyzed over 99,000 genomic analyses[31] - Total data processed on SOPHiA DDM™ has seen compounded growth of over 50% since 2021[38] Financial Performance and Outlook - The company's revenue for 2024 was $65.2 million[56] - Revenue is expected to be in the range of $75 million to $77 million in 2025, representing year-over-year growth of 15% to 18%[59] - Adjusted gross margin was 72.8% in 2024[59] and 73.1% in Q3 2025[63] - The company has a cash balance of $81.6 million as of Q3 2025[63]

Company Overview - SOPHiA GENETICS' Ai platform SOPHiA DDM™ is used by over 800 healthcare institutions globally to analyze complex health data for cancer and rare disorders[7] - The platform analyzes over 350,000 patients annually and has analyzed over 2 million profiles since its inception[8, 21] - The company has invested over $450 million since its inception in its Ai platform[21, 57] Market Trends - The incidence of cancer and rare disorders is increasing worldwide, driving demand for targeted therapies[13] - Healthcare data is rapidly expanding, with 30% of all data generated globally being healthcare-related[16] - The Total Addressable Market (TAM) for Liquid Biopsy is estimated to be over $5 billion[56] Financial Performance - SOPHiA GENETICS' revenue for 2024 was $65.2 million[60] - The company projects revenue between $72 million and $76 million for 2025, representing a year-over-year growth of approximately 10% to 17%[60, 63] - Adjusted EBITDA loss is projected to be between $35 million and $39 million in 2025, compared to $40.2 million in 2024[63] - The company's adjusted gross margin was 72.8% in 2024 and is expected to expand slightly in 2025[63]

Financial Performance - SOPHiA GENETICS reported Q2 2025 revenue of $18.3 million, reflecting a 16% year-over-year growth [7][12] - Adjusted gross margin improved to 74.4%, up 120 basis points from the previous year [3][12] - The company experienced a net loss of $22.4 million, which is a 48% increase year-over-year [7][12] Business Highlights - The company signed 35 new core genomics customers in Q2 2025, a significant increase from 19 new customers in Q2 2024 [3][8] - A major multi-year AI breast cancer partnership was established with AstraZeneca, marking the largest contract in the company's history [3][12] - The total number of core genomics customers reached 490 as of June 30, 2025, up from 457 at the end of Q2 2024 [8] Operational Efficiency - Cash burn improved by 35% year-over-year, totaling $8.7 million for the quarter [3][7] - The company performed 95,000 analyses on SOPHiA DDMTM, representing a 9% year-over-year volume growth [8] - The partnership with Dasa, the largest medical diagnostics company in Latin America, was expanded to include additional applications [8] Future Outlook - SOPHiA GENETICS reaffirmed its full-year revenue guidance of $72 million to $76 million, indicating a growth of approximately 10% to 17% compared to FY 2024 [12] - The company expects to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027 [12]

Company Overview and Platform - SOPHiA GENETICS's AI platform SOPHiA DDM is used by over 800 healthcare institutions globally [7] - The platform analyzes over 350,000 patients per year and has analyzed over 2 million profiles since inception [8, 21] - The company has invested over $450 million since inception in its AI platform [21] Market Trends and Data Analysis - Healthcare data accounts for 30% of all data generated globally [17] - In 2024, SOPHiA DDM performed over 350,000 genomic analyses, with over 93,000 in Q1 2025 [33] - Total data processed on SOPHiA DDM has seen compounded growth of over 50% since 2021 [46] Financial Performance and Outlook - SOPHiA GENETICS' revenue for 2024 was $65.2 million [68] - The company projects revenue between $72 million and $76 million for 2025, representing approximately 10% to 17% year-over-year growth [71] - Adjusted gross margin was 72.8% in 2024 and is expected to expand slightly in 2025 [71] - The company had a cash balance of $68.5 million as of Q1 2025 [76]

Core Insights - SOPHiA GENETICS reported a strong start to 2025 with a year-over-year revenue growth of 13%, or 15% on a constant currency basis, driven by new business signed in 2024 [3][7] - The company achieved a record adjusted gross margin of 75.7%, up 520 basis points year-over-year, indicating effective cost management and operational efficiency [3][7] - The company continues to focus on long-term growth prospects, particularly in the U.S. market, where revenue from core genomics customers grew over 30% [3][13] Financial Performance - Revenue for Q1 2025 was $17.8 million, reflecting a 13% increase from $15.8 million in Q1 2024 [7][35] - Adjusted EBITDA loss improved by 24% year-over-year to $9.8 million, demonstrating progress towards profitability [7][33] - The company reaffirms its full-year revenue guidance of $72 million to $76 million, representing a growth of approximately 10% to 17% compared to FY 2024 [7][13] Business Highlights - SOPHiA DDM™ platform performed 93,000 analyses in Q1 2025, marking an 11% year-over-year volume growth [8] - The company onboarded 33 new core genomics customers in Q1 2025, up from an average of 23 customers per quarter in 2024 [8] - Significant demand for new applications, including the Liquid Biopsy application MSK-ACCESS®, has led to a healthy pipeline of over 60 identified opportunities [9][10] Market Expansion - The company expanded its collaboration with AstraZeneca to accelerate the deployment of MSK-ACCESS® globally, now involving 30 sponsored institutions [8] - New customers were signed across various geographies, including notable institutions in Belgium, Canada, and Malaysia [8][9] - The U.S. market continues to show strong business growth, with a focus on operational excellence and sustainable growth strategies [10][11]